Protara Therapeutics Inc. Common Stock (TARA)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I start with the business, not the story. Protara is a clinical-stage biopharmaceutical company with 46 employees, advancing TARA-002 in Phase II for non-muscle invasive bladder cancer and lymphatic malformations, plus intravenous choline chloride. There is no revenue in any filed period I was given. In fiscal 2025, the year ended 2025-12-31, net loss was $57.4 million; in fiscal 2024 it was $44.6 million; in fiscal 2023 it was $40.4 million. The loss is widening, not narrowing. In the first half of fiscal 2026, the quarters ended 2026-03-31 and 2026-06-30, net losses were $17.8 million and $21.7 million. That is not a business with a moat yet; it is a collection of binary scientific options. Financial health is mixed. Debt is low, with D/E of 0.02, and the Altman Z-Score is 4.47 per FairStock, but trailing free cash flow is -$66.5 million and the FCF yield is -42.9%. At the 2026-10-13 close of $2.62, market cap is $154.8 million. FairStock shows P/B 0.96, P/E -1.93, ROE -45.80%, ROCE -28.82%, and a Piotroski F-Score of 1/9. The P/B near 1 suggests the stock is valued near book, but that book is being consumed by cash burn. FairStock's Lynch category is none — loss in each of the last 4 years — which is honest. Growth is not revenue growth; it is spending growth while waiting for trial data. Without positive data or a partner, more equity is likely. I would need a margin of safety well beyond a low price to compensate for that uncertainty.

In plain English: Protara Therapeutics is a small clinical-stage biotech testing cell therapy and a replacement therapy, mainly for bladder cancer and rare lymphatic malformations. It has no product revenue, has lost money for years, and is using cash quickly, so the business looks weak today. At $2.62, the price is near the accounting value of its net assets, but with no profits and heavy spending, it is not obviously cheap; much depends on future trial results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer